The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Fluorine-18     fluorane

Synonyms: CHEBI:36939, AC1L2Y5H, (18)F, (18)9F, Fluorine, isotope of mass 18, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of hydrogen fluoride

 

Psychiatry related information on hydrogen fluoride

 

High impact information on hydrogen fluoride

 

Chemical compound and disease context of hydrogen fluoride

 

Biological context of hydrogen fluoride

 

Anatomical context of hydrogen fluoride

 

Associations of hydrogen fluoride with other chemical compounds

 

Gene context of hydrogen fluoride

 

Analytical, diagnostic and therapeutic context of hydrogen fluoride

References

  1. PET with fluorine-18 deoxyglucose for pancreatic disease. Klever, P., Bares, R., Fass, J., Büll, U., Schumpelick, V. Lancet (1992) [Pubmed]
  2. 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Skehan, S.J., Issenman, R., Mernagh, J., Nahmias, C., Jacobson, K. Lancet (1999) [Pubmed]
  3. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Peñuelas, I., Mazzolini, G., Boán, J.F., Sangro, B., Martí-Climent, J., Ruiz, M., Ruiz, J., Satyamurthy, N., Qian, C., Barrio, J.R., Phelps, M.E., Richter, J.A., Gambhir, S.S., Prieto, J. Gastroenterology (2005) [Pubmed]
  4. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Kissel, J., Brix, G., Bellemann, M.E., Strauss, L.G., Dimitrakopoulou-Strauss, A., Port, R., Haberkorn, U., Lorenz, W.J. Cancer Res. (1997) [Pubmed]
  5. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. Avril, N., Rosé, C.A., Schelling, M., Dose, J., Kuhn, W., Bense, S., Weber, W., Ziegler, S., Graeff, H., Schwaiger, M. J. Clin. Oncol. (2000) [Pubmed]
  6. Gilles de la tourette syndrome: studies with the fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method. Chase, T.N., Foster, N.L., Fedio, P., Brooks, R., Mansi, L., Kessler, R., Di Chiro, G. Ann. Neurol. (1984) [Pubmed]
  7. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Kuhl, D.E., Metter, E.J., Riege, W.H., Markham, C.H. Ann. Neurol. (1984) [Pubmed]
  8. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. Ketter, T.A., Kimbrell, T.A., George, M.S., Willis, M.W., Benson, B.E., Danielson, A., Frye, M.A., Herscovitch, P., Post, R.M. Biol. Psychiatry (1999) [Pubmed]
  9. Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET. Kushner, M., Tobin, M., Alavi, A., Chawluk, J., Rosen, M., Fazekas, F., Alavi, J., Reivich, M. J. Nucl. Med. (1987) [Pubmed]
  10. Interictal 18FDG PET findings in temporal lobe epilepsy with déjà vu. Adachi, N., Koutroumanidis, M., Elwes, R.D., Polkey, C.E., Binnie, C.D., Reynolds, E.H., Barrington, S.F., Maisey, M.N., Panayiotopoulos, C.P. The Journal of neuropsychiatry and clinical neurosciences. (1999) [Pubmed]
  11. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Yatham, L.N., Liddle, P.F., Dennie, J., Shiah, I.S., Adam, M.J., Lane, C.J., Lam, R.W., Ruth, T.J. Arch. Gen. Psychiatry (1999) [Pubmed]
  12. Myocardial rubidium-82 tissue kinetics assessed by dynamic positron emission tomography as a marker of myocardial cell membrane integrity and viability. vom Dahl, J., Muzik, O., Wolfe, E.R., Allman, C., Hutchins, G., Schwaiger, M. Circulation (1996) [Pubmed]
  13. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. Wahl, R.L., Siegel, B.A., Coleman, R.E., Gatsonis, C.G. J. Clin. Oncol. (2004) [Pubmed]
  14. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report. Miceli, M., Atoui, R., Walker, R., Mahfouz, T., Mirza, N., Diaz, J., Tricot, G., Barlogie, B., Anaissie, E. J. Clin. Oncol. (2004) [Pubmed]
  15. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., Verhoef, G. J. Clin. Oncol. (2001) [Pubmed]
  16. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. Gropler, R.J., Geltman, E.M., Sampathkumaran, K., Pérez, J.E., Schechtman, K.B., Conversano, A., Sobel, B.E., Bergmann, S.R., Siegel, B.A. J. Am. Coll. Cardiol. (1993) [Pubmed]
  17. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. Shelton, M.E., Dence, C.S., Hwang, D.R., Herrero, P., Welch, M.J., Bergmann, S.R. J. Am. Coll. Cardiol. (1990) [Pubmed]
  18. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. Liu, A., Carlson, K.E., Katzenellenbogen, J.A. J. Med. Chem. (1992) [Pubmed]
  19. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. Imahori, Y., Ueda, S., Ohmori, Y., Kusuki, T., Ono, K., Fujii, R., Ido, T. J. Nucl. Med. (1998) [Pubmed]
  20. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. Haberkorn, U., Bellemann, M.E., Altmann, A., Gerlach, L., Morr, I., Oberdorfer, F., Brix, G., Doll, J., Blatter, J., van Kaick, G. J. Nucl. Med. (1997) [Pubmed]
  21. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. Baer, F.M., Voth, E., Deutsch, H.J., Schneider, C.A., Horst, M., de Vivie, E.R., Schicha, H., Erdmann, E., Sechtem, U. J. Am. Coll. Cardiol. (1996) [Pubmed]
  22. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. Bax, J.J., Cornel, J.H., Visser, F.C., Fioretti, P.M., van Lingen, A., Huitink, J.M., Kamp, O., Nijland, F., Roelandt, J.R., Visser, C.A. J. Am. Coll. Cardiol. (1997) [Pubmed]
  23. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Imahori, Y., Ueda, S., Ohmori, Y., Sakae, K., Kusuki, T., Kobayashi, T., Takagaki, M., Ono, K., Ido, T., Fujii, R. Clin. Cancer Res. (1998) [Pubmed]
  24. Synthesis, binding properties, and 18F labeling of fluorocarazolol, a high-affinity beta-adrenergic receptor antagonist. Zheng, L., Berridge, M.S., Ernsberger, P. J. Med. Chem. (1994) [Pubmed]
  25. Hibernating myocardium versus scar: severity of irreversible decreased myocardial perfusion in prediction of tissue viability. Go, R.T., MacIntyre, W.J., Saha, G.B., Cook, S.A., Neumann, D.R., Chen, E.Q., Underwood, D.A., Kaczur, T. Radiology. (1995) [Pubmed]
  26. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Hällsten, K., Virtanen, K.A., Lönnqvist, F., Sipilä, H., Oksanen, A., Viljanen, T., Rönnemaa, T., Viikari, J., Knuuti, J., Nuutila, P. Diabetes (2002) [Pubmed]
  27. Assessment of viable myocardium by dobutamine transesophageal echocardiography and comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. Baer, F.M., Voth, E., Deutsch, H.J., Schneider, C.A., Schicha, H., Sechtem, U. J. Am. Coll. Cardiol. (1994) [Pubmed]
  28. The effect of the Ala12 allele of the peroxisome proliferator-activated receptor-gamma2 gene on skeletal muscle glucose uptake depends on obesity: a positron emission tomography study. Vänttinen, M., Nuutila, P., Pihlajamäki, J., Hällsten, K., Virtanen, K.A., Lautamäki, R., Peltoniemi, P., Kemppainen, J., Takala, T., Viljanen, A.P., Knuuti, J., Laakso, M. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  29. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. Joensuu, H., Ahonen, A. J. Nucl. Med. (1987) [Pubmed]
  30. Magnetic resonance and fluorine-18 deoxyglucose imaging in the investigation of a spinal cord tumor. Alavi, A., Kramer, E., Wegener, W., Alavi, J. J. Nucl. Med. (1990) [Pubmed]
  31. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Chase, T.N., Foster, N.L., Fedio, P., Brooks, R., Mansi, L., Di Chiro, G. Ann. Neurol. (1984) [Pubmed]
  32. The use of positron emission tomographic scanning in epilepsy. Engel, J. Ann. Neurol. (1984) [Pubmed]
  33. A fluorine-18 labeled progestin as an imaging agent for progestin receptor positive tumors with positron emission tomography. Verhagen, A., Elsinga, P.H., de Groot, T.J., Paans, A.M., de Goeij, C.J., Sluyser, M., Vaalburg, W. Cancer Res. (1991) [Pubmed]
  34. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography. Sandler, M.P., Videlefsky, S., Delbeke, D., Patton, J.A., Meyerowitz, C., Martin, W.H., Ohana, I. J. Am. Coll. Cardiol. (1995) [Pubmed]
  35. T wave normalization in infarct-related electrocardiographic leads during exercise testing for detection of residual viability: comparison with positron emission tomography. Mobilia, G., Zanco, P., Desideri, A., Neri, G., Alitto, F., Suzzi, G., Chierichetti, F., Celegon, L., Ferlin, G., Buchberger, R. J. Am. Coll. Cardiol. (1998) [Pubmed]
  36. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Otonkoski, T., Näntö-Salonen, K., Seppänen, M., Veijola, R., Huopio, H., Hussain, K., Tapanainen, P., Eskola, O., Parkkola, R., Ekström, K., Guiot, Y., Rahier, J., Laakso, M., Rintala, R., Nuutila, P., Minn, H. Diabetes (2006) [Pubmed]
  37. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Jonson, S.D., Welch, M.J. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). (1998) [Pubmed]
  38. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Goodman, M.M., Kilts, C.D., Keil, R., Shi, B., Martarello, L., Xing, D., Votaw, J., Ely, T.D., Lambert, P., Owens, M.J., Camp, V.M., Malveaux, E., Hoffman, J.M. Nucl. Med. Biol. (2000) [Pubmed]
  39. Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography of the brain, MR spectroscopy, and therapeutic attempts in methylenetetrahydrofolate reductase deficiency. Al-Essa, M.A., Al Amir, A., Rashed, M., Al Jishi, E., Abutaleb, A., Mobaireek, K., Shin, Y.S., Ozand, P.T. Brain Dev. (1999) [Pubmed]
  40. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Wester, H.J., Schottelius, M., Scheidhauer, K., Meisetschläger, G., Herz, M., Rau, F.C., Reubi, J.C., Schwaiger, M. Eur. J. Nucl. Med. Mol. Imaging (2003) [Pubmed]
  41. Evolutional changes of cortical hypometabolism in West's syndrome. Maeda, N., Watanabe, K., Negoro, T., Aso, K., Ohki, T., Ito, K., Kato, T. Lancet (1994) [Pubmed]
  42. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Dann, E.J., Bar-Shalom, R., Tamir, A., Haim, N., Ben-Shachar, M., Avivi, I., Zuckerman, T., Kirschbaum, M., Goor, O., Libster, D., Rowe, J.M., Epelbaum, R. Blood (2007) [Pubmed]
  43. Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. Garg, P.K., Garg, S., Bigner, D.D., Zalutsky, M.R. Cancer Res. (1992) [Pubmed]
  44. Progestin 16 alpha, 17 alpha-dioxolane ketals as molecular probes for the progesterone receptor: synthesis, binding affinity, and photochemical evaluation. Kym, P.R., Carlson, K.E., Katzenellenbogen, J.A. J. Med. Chem. (1993) [Pubmed]
 
WikiGenes - Universities